Miruvor
Sign up
The short answer

What studies of clonidine found

9papers on clonidine
66people in 3 studies testing clonidine alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: D Little or no difference

Based on the strongest evidence, the placebo trial and studies with no comparison group (very low certainty): 1 of 2 findings is D, a tie, so the grade of autonomic symptoms, as the rule below says.

1 outcome rated · see each below

Both together: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.

6 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For ME/CFS, studies found little or no difference with clonidine. For long COVID and ME/CFS studied together, clonidine might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 9 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Clonidine · Both together is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Clonidine · ME/CFS is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Autonomic symptoms2 studies · 65 people took clonidine Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 120 people found no clear difference; a small benefit can't be ruled out.

The placebo trial120 randomised · week 8 · 50 μg B.I.D for body weight >35 kg, and 25 μg B.I.D for body weight < 35 kg

No clear difference in autonomic symptoms.

The evidence is very uncertain about the effect of clonidine on autonomic symptoms in ME/CFS. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 120 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group5 in the study · 14 days · 50 μg, twice per day (BID) (few people)

Autonomic symptoms improved.

The evidence is very uncertain about the effect of clonidine on autonomic symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (5 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue: a randomized controlled trial. (2015)

    People in the study
    120 randomised
    Dose
    50 μg B.I.D for body weight >35 kg, and 25 μg B.I.D for body weight < 35 kg
    Outcome
    Orthostatic symptoms – total score Autonomic Symptom Profile (ASP)
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial. (2012)

    People in the study
    5 in the study
    Dose
    50 μg, twice per day (BID)
    Outcome
    LF/HF
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Both together

Symptoms

Autonomic symptoms1 study · 1 (few people) person took clonidine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Autonomic symptoms improved.

The evidence is very uncertain about the effect of clonidine on autonomic symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    peak heart rate when walking on cromolyn
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person took clonidine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Pain improved.

The evidence is very uncertain about the effect of clonidine on pain in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    remaining symptoms at one year
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 1 (few people) person took clonidine Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Too little to say about cognition (brain fog).

Too little to say: cognition (brain fog) got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took clonidine Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance; one study saw it get worse, without a test against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Too little to say about fatigue.

Too little to say: fatigue got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    fatigue and cognitive dysfunction on stopping fexofenadine and famotidine
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 1 (few people) person took clonidine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of clonidine on daily functioning in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    energy and overall function on naltrexone
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took clonidine Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all).

Studies with no comparison group1 in the study · over 30 months · low doses (few people)

Overall symptoms improved.

The evidence is very uncertain about the effect of clonidine on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
See the 1 study
  1. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID. (2023)

    People in the study
    1 in the study
    Dose
    low doses
    Outcome
    symptom improvement over 30 months
    Effect
    better
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported4 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Dizziness2 studies
Fatigue2 studies
Trouble sleeping2 studies
Worse symptoms or a flare1 study

All papers

  1. Genetic variation in catechol-O-methyltransferase modifies effects of clonidine treatment in chronic fatigue syndrome.2016 · placebo trial · 120 randomised · 104 analysed
    Summary

    This randomized double-blinded trial compared clonidine with placebo in 120 CFS patients aged 12–18 years at Oslo University Hospital, Norway, between 1 March 2010 and 15 October 2012. The study examined whether COMT rs4680 genotype modifies clonidine treatment outcomes. Clonidine was given as 25 or 50 μg twice daily for 8 weeks. Data from 104 patients genotyped at baseline were available for primary end point evaluation at week 8. The primary outcome was Steps Taken, the mean number of steps per day; secondary outcomes included the Karolinska Sleep Questionnaire (KSQ), Pediatric Quality of Life (PedsQL), Chalder Fatigue Questionnaire (CFQ), Functional Disability Inventory (FDI) and Brief Pain Inventory (BPI), plus orthostatic tolerance. Among patients homozygous for the rs4680 high-activity allele (val/val), those randomized to clonidine took 2500 fewer steps compared with placebo (Pinteraction = 0.04). In the unadjusted model, val/val patients on clonidine took ∼1500 fewer steps than baseline, whereas those on placebo took 1000 more steps after 8 weeks (β (s.e.) = −2026 (990); Pinteraction = 0.043). There were no differences between clonidine and placebo among patients with COMT low-activity alleles. Sleep quality of val/val adolescents worsened with 8 weeks of clonidine versus placebo treatment (KSQ β (s.e.) = −1.25 (0.42), Pint = 0.003), and val/val individuals had overall worse outcomes in the clonidine treatment arm compared with placebo (PedsQL β (s.e.) = −14.2 (5.9), Pint = 0.018). CFQ, FDI and BPI effects were nonsignificant. Val/val patients on clonidine had a decrease in orthostatic tolerance compared with placebo (β (s.e.) = −11.5 (5.0), P=0.02). Withdrawals for harms were not reported.

  2. Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue: a randomized controlled trial.2015 · placebo trial · 120 randomised
    Summary

    This randomized controlled trial examined low-dose clonidine in adolescents aged 12–18 years with chronic fatigue syndrome at a national referral center at Oslo University Hospital. A total of 120 patients were enrolled and started treatment, 60 in the clonidine group and 60 in the placebo group. Patients received oral clonidine capsules (25 μg or 50 μg twice daily for body weight below/above 35 kg) or placebo capsules for 9 weeks; results are reported from week 8. The study measured symptom scores, catecholamines, and cardiovascular variables during supine rest and 20° head-up tilt. At week 8, the clonidine group had lower plasma norepinephrine (difference −205 pmol/L, p = 0.05) and lower urine norepinephrine/creatinine ratio (difference −3.9 nmol/mmol, p = 0.002) than placebo. During supine rest, the clonidine group had higher LF-HRV in absolute units (ratio 1.4, p = 0.007) and higher SDNN (difference 12.0 ms, p = 0.05). Symptoms of orthostatic intolerance did not change; the total score difference was −0.05 (p = 0.84). During 20° head-up tilt there were no statistical differences in any cardiovascular variable. There were 5 drop-outs in the clonidine group and 9 in the placebo group; side effects were not reported. The authors state a possible limitation is wide inclusion criteria and no a priori-definition of school absenteeism necessary for diagnostic criteria.

  3. Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial.2014 · placebo trial · 120 randomised
    Summary

    Adolescents with chronic fatigue syndrome were enrolled from a single referral center recruiting nationwide in Norway. The study combined a cross-sectional comparison and a randomized clinical trial. In the trial, 120 patients started treatment, 60 allocated to clonidine and 60 to placebo. Clonidine hydrochloride capsules were given orally at 25 µg or 50 µg twice daily for body weight <35 kg or >35 kg, respectively, for 9 weeks; placebo capsules were the comparator. The primary efficacy end point was mean number of steps per day. At week 8, the clonidine group had a lower number of steps per day (mean difference, -637 steps; P = .07) than the placebo group. Plasma norepinephrine was lower (mean difference, -42 pg/mL; P = .01) and serum CRP was lower (mean ratio, 0.69; P = .02) with clonidine. The clonidine group had lower supine and upright heart rates at week 8 (P = .03 and P = .03, respectively). At week 30, lower heart rate responsiveness was found in the clonidine group (P = .03). Fourteen patients dropped out before week 8 (5 clonidine, 9 placebo), and an additional 3 withdrew before week 30. Sleepiness and dizziness when rising were significantly more common in the clonidine group, but there was no significant difference in total self-reported adverse effects. In the clonidine group, one patient fainted and another had a peptic duodenal ulcer immediately after the intervention period.

  4. Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial.2012 · no comparison group · 5 in the study
    Summary

    This open, uncontrolled pilot study enrolled five adolescents with chronic fatigue syndrome (14–19 years old; median age 14 years; median disease duration 34 months) from the Pediatric outpatient clinic, Oslo University Hospital, Rikshospitalet, Norway. Participants received 50 μg clonidine twice per day during 14 days; there was no comparison group. Assessments included plasma clonidine concentration assays, a 20 deg. head-up tilt-test, and adverse effects mapped by a questionnaire. After 14 days, median HR at supine rest was 69.5 before and 65.4 during clonidine; MBP was 76.1 and 74.0; DBP was 62.1 and 59.1; SI was 50.4 and 42.7. The text reports a slight reduction in median HR, MBP, DBP and SI at baseline during clonidine treatment and that the HUT response was closer to the normal response. No serious adverse effects were registered. All patients reported dry eyes; two reported dry mouth; three reported a change in sleeping pattern; one reported sleepiness at daytime; one experienced increased fatigue; one described slight dizziness; no participant experienced syncope. No statistical tests were carried out. The study was open-label and uncontrolled, with a small number of participants; the authors state this does not allow firm conclusions.

  5. A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.2023 · case report · 1 in the study
    Summary

    This case study reports a 19-year-old male who developed impairment consistent with ME/CFS after SARS-CoV-2 infection. The study reports one patient; there was no comparison group, and outcomes were before-versus-after over 30 months. Treatment included physical therapy; stationary biking and running as graded activity; oral sodium chloride and lower limb compression garments; and medications/supplements: fludrocortisone, midodrine, atenolol, pyridostigmine bromide, ivabradine, clonidine, methylphenidate, fexofenadine, famotidine, cromolyn, quercetin, escitalopram, and naltrexone. The paper reports significant improvement in symptoms over 30 months. With cromolyn, peak walking heart rate fell from the 130–140 bpm range to 100–105 bpm. Stopping fexofenadine and famotidine was accompanied on more than one occasion by increased fatigue and cognitive dysfunction; stopping H1 and H2 antihistamines was associated with worsened concentration and short-term memory. Naltrexone was associated with improved energy and overall function, and the patient reported improvements with low doses of clonidine and methylphenidate. For the first 15 months after infection, he continued to have exercise intolerance, with heart rate reaching 130–150 bpm during each of two 15-min walks daily. At one year, remaining symptoms included daily fatigue; lightheadedness and headaches were infrequent. He later resumed running at 10 min four times a week, increased running by two minutes each week, and in October 2022 competed in an 8 K event. Adverse effects were reported with fludrocortisone, midodrine, atenolol, pyridostigmine bromide, and ivabradine. Limitations stated include possible spontaneous improvement and uncertainty about independent effects of interventions.

  6. A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.2016 · systematic review
    Summary

    This systematic review examined drug therapies for chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME). Ovid MEDLINE, EMBASE, and PubMed were searched from the beginning of their archives to March 2016. The review included 26 randomized, placebo-controlled trials that met its criteria; these trials tested 20 drug therapies. The review reports effectiveness by categories from not effective to highly effective and says no universal pharmaceutical treatment can be recommended. Hydrocortisone findings were conflicting: across studies it was reported as mildly effective, slightly effective, not effective, and moderately effective; in one study the well-being improvement was not significant, and Blockmans et al found no clinical improvement. Rituximab was reported to produce a significant and lasting improvement, but the review states it is premature to conclude a lasting improvement in primary assessed domains; primary end points were evaluated for 3 months and secondary end points up to 12 months. For intravenous immunoglobulin, Rowe reported headache, fatigue, and difficulty concentrating significantly worse in the intervention group after the first infusion, with no differences after the third and final infusion. The review states no pharmaceutical therapy resulted in severe adverse events. It notes nefazodone was discontinued in 2004 after patients developed hepatic and visual disorders. Forsyth et al and Young each had N = 26; Young lacked male participants in the intervention cohort. The authors state that no clear recommended pharmaceutical therapy for CFS/ME exists and call for standardized diagnostic criteria and outcome measurements.

  7. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
    Summary

    This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.

  8. Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?2010 · review
    Summary

    This review examined pharmacotherapy for chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME), focusing on non-antidepressant controlled drug trials published between 1988 and August 2009. It did not report one overall number of enrolled patients. In the methylphenidate trial (60 CFS patients), clinically significant improvement on the Checklist of Individual Strength concentration subscale occurred in 13 patients taking methylphenidate (22%) versus three taking placebo (5%; p = 0.01); the number needed to treat was 6 [95% CI: 4.6 to 8.6]. A clinically significant fatigue response occurred in 10 patients (17%) with methylphenidate versus no patients with placebo; the number needed to treat was 6 (95% CI: 3.8 to 14.4). No effect was observed on bodily pain, mental health, depression and anxiety, and no severe side effects were reported. Other reviewed trials reported no significant effect for aciclovir, no beneficial effects for ganciclovir, no differences versus placebo for oral terfenadine (n = 30), and no effect for immunoglobulin in a large RCT (n = 99). In a doxycycline RCT (n = 491), there were no statistically significant differences versus placebo; the doxycycline group had a higher incidence of nausea and photosensitivity. Two participants in a magnesium RCT (n = 34) dropped out, one because of generalized rash.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime